Subcutaneous testosterone effective HT for transgender male, gender-diverse youths

Sumary of Subcutaneous testosterone effective HT for transgender male, gender-diverse youths:

  • Subcutaneous testosterone was effective in allowing transgender male and gender-diverse youths to reach recommended testosterone levels and stop menses, with few severe adverse events, according to findings published in Transgender Health..
  • Adobe Stock “Generic forms of injectable testosterone (cypionate and enanthate) are approved only for intramuscular use, even though both formulations have been used off-label for subcutaneous application in transgender care for years,”.
  • Laurenzano, MD, a pediatric endocrinologist at the University of New Mexico and former fellow in pediatric endocrinology at the University of California, San Diego, and Maja Marinkovic, MD, associate clinical professor in the department of pediatric endocrinology at the University of California, San Diego, and medical co-director of the Center for Gender Affirming Care at Rady Children Hospital-San Diego, told Healio..
  • Confirming safety and efficacy of subcutaneous testosterone may increase compliance as compared to the deeper and often more painful intramuscular injections.”.
  • Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as gender-affirming HT in transgender males and gender-diverse youths at Rady Children Hospital-San Diego..
  • A total of 119 participants who were younger than 21 years when starting testosterone and received testosterone for at least 6 months between August 2012 and February 2020 were included..
  • Researchers obtained BMI, BMI z scores, testosterone levels and laboratory levels at the start of HT as well as at follow-up, defined as the last date testosterone levels were checked..
  • Recommended levels reached, menses cessation for most Of the study population, 79% received 100 mg to 200 mg of testosterone monthly at last follow-up, and 18% received 240 mg to 320 mg monthly..
  • HT started with 25 mg to 50 mg biweekly doses and were increased every 3 to 6 months based on testosterone levels, patient preference and the timing of follow-up..
  • For those receiving at least 200 mg of testosterone monthly, the mean total testosterone level was 460 ng/dL and the mean free testosterone level was at 92 pg/mL..
  • There was no difference in testosterone levels between those on weekly dosing and those still receiving biweekly doses at last follow-up..
  • Of 78 participants with data on menses status, all but two had cessation of menses with a 200 mg monthly dose of subcutaneous testosterone, and 53.9% had cessation of menses with a monthly dose of 140 mg….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close